Latham & Watkins Advises on ANI Pharmaceuticals’ Upsized US$316.25 Million Convertible Senior Notes Offering

ANI Pharmaceuticals, Inc. (ANI) (Nasdaq: ANIP) has announced the closing of its offering of US$316.25 million aggregate principal amount of 2.25% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. In response to investor demand, ANI upsized the initial offering of US$250 million aggregate principal amount of notes to US$275 million and the initial purchasers fully exercised their option to purchase an additional US$41.25 million aggregate principal amount of the notes.

Latham & Watkins LLP represented the initial purchasers in the offering with a capital markets team led by New York/Los Angeles partner Greg Rodgers, Los Angeles partner Arash Aminian Baghai, and Century City partner Brent Epstein, with associates Andrew Bentz, Eric Finkelberg, and Dylan Shamoon. Advice was also provided on equity derivatives matters by New York partner Reza Mojtabaee-Zamani, with associate Kevin Zhang; on tax matters by New York partners Elena Romanova and Aaron Bernstein, with associates Tessa Young and James Aldred; on environmental matters by Los Angeles partner Aron Potash, with associate Qingyi Pan; on FDA matters by Washington, D.C. counsel Chad Jennings and Washington, D.C. of counsel Carolyne Hathaway, with associate Trevor Thompson; on healthcare regulatory matters by Bay Area partner Betty Pang; on intellectual property matters by New York partner Jeffrey Tochner, with associate Pelin Serpin; on cybersecurity matters by Bay Area partner Heather Deixler, with associate Mitch Bennett; and on compensation and benefits matters by Chicago partner Benjamin Rosemergy, with associate Joseph Benedetto.